China Pharmaceutical Quality Control Market

ID: MRFR/Pharma/46840-HCR
200 Pages
Vikita Thakur
Last Updated: April 06, 2026
China Pharmaceutical Quality Control Market Research Report: By Product (Consumable, Instruments, Services), By Analysis Type (Sterility Testing, Bioburden Testing, Endotoxin Testing, Stability Testing, Extractable & Leachable Testing, Raw Material Testing, Others) andBy Products Tested (Vaccines, Plasma Product, Drugs) - Growth & Industry Forecast 2025 To 2035
China Pharmaceutical Quality Control Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)8.67%
2024 Market Size$ 190.64 Million
2025 Market Size$ 207.17 Million
2035 Market Size$ 475.6 Million
Key Players
Thermo Fisher Scientific
Abbott Laboratories
Roche Holding AG
Siemens Healthineers
Danaher Corporation
PerkinElmer Inc.
Opportunities
  • Consumer Awareness and Advocacy
  • Stringent Regulatory Frameworks
  • Growing Biopharmaceutical Sector
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Construction, BY Product (USD Million)
      1. 4.1.1 Consumables
      2. 4.1.2 Instruments
      3. 4.1.3 Services
    2. 4.2 Construction, BY Analysis Type (USD Million)
      1. 4.2.1 Sterility Testing
      2. 4.2.2 Bioburden Testing
      3. 4.2.3 Endotoxin Testing
      4. 4.2.4 Stability Testing
      5. 4.2.5 Extractable & Leachable Testing
      6. 4.2.6 Raw Material Testing
      7. 4.2.7 Others
    3. 4.3 Construction, BY Products Tested (USD Million)
      1. 4.3.1 Vaccines
      2. 4.3.2 Plasma Product
      3. 4.3.3 Drugs
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Construction
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Thermo Fisher Scientific (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Abbott Laboratories (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche Holding AG (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Siemens Healthineers (DE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Danaher Corporation (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 PerkinElmer Inc. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Merck KGaA (DE)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Agilent Technologies (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Bio-Rad Laboratories (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 CHINA MARKET ANALYSIS BY PRODUCT
    3. 6.3 CHINA MARKET ANALYSIS BY ANALYSIS TYPE
    4. 6.4 CHINA MARKET ANALYSIS BY PRODUCTS TESTED
    5. 6.5 KEY BUYING CRITERIA OF CONSTRUCTION
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF CONSTRUCTION
    8. 6.8 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
    10. 6.10 SUPPLY / VALUE CHAIN: CONSTRUCTION
    11. 6.11 CONSTRUCTION, BY PRODUCT, 2024 (% SHARE)
    12. 6.12 CONSTRUCTION, BY PRODUCT, 2024 TO 2035 (USD Million)
    13. 6.13 CONSTRUCTION, BY ANALYSIS TYPE, 2024 (% SHARE)
    14. 6.14 CONSTRUCTION, BY ANALYSIS TYPE, 2024 TO 2035 (USD Million)
    15. 6.15 CONSTRUCTION, BY PRODUCTS TESTED, 2024 (% SHARE)
    16. 6.16 CONSTRUCTION, BY PRODUCTS TESTED, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY PRODUCT, 2025-2035 (USD Million)
      2. 7.2.2 BY ANALYSIS TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY PRODUCTS TESTED, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

China Pharmaceutical Quality Control Market Segmentation

China Pharmaceutical Quality Control Market By Product (USD Million, 2025-2035)

  • Consumables
  • Instruments
  • Services

China Pharmaceutical Quality Control Market By Analysis Type (USD Million, 2025-2035)

  • Sterility Testing
  • Bioburden Testing
  • Endotoxin Testing
  • Stability Testing
  • Extractable & Leachable Testing
  • Raw Material Testing
  • Others

China Pharmaceutical Quality Control Market By Products Tested (USD Million, 2025-2035)

  • Vaccines
  • Plasma Product
  • Drugs
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.